Last Updated : April 28, 2025
Details
Generic Name:
tislelizumab
Project Status:
Pending
Therapeutic Area:
recurrent or metastatic nasopharyngeal carcinoma
Manufacturer:
BeiGene (Canada) ULC
Call for patient/clinician input open:
Project Line:
Reimbursement Review
Project Number:
PC0399-000
Call for patient/clinician input closed:
Tumour Type:
Head and Neck
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Tislelizumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), and then as a single agent after up to 6 cycles of combination therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Tislelizumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), and then as a single agent after up to 6 cycles of combination therapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : April 28, 2025